
Neurocrine Biosciences rose 19.7% from $138.63 to $165.92, ahead of the S&P 500's +11.0%. Its worst day was Feb 12 (−10.4%), and its low came Feb 12 at $123.10.
Nov 18, 2025 – Nov 17, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
Neurocrine Biosciences shares rose 5.6%, while the S&P 500 rose 0.7%.
+5.6% · S&P 500 +0.7%
EPS of $1.88 missed the $2.09 estimate on $805.5M revenue (est. $786.7M).
−10.4%, the year's worst day · S&P 500 −1.5%
Story events cover the past 12 months · Times ET
EPS of $1.94 beat the $1.61 estimate on $814.5M revenue (est. $763.1M).
+8.9% · S&P 500 +1.4%
Analyses span adult and pediatric populations with classic congenital adrenal hyperplasia (CAH) and reflect longer-term clinical outcomes relevant to disease management across lifespan and care continuumNew data
+6.6% · S&P 500 −0.7%
EPS of $2.85 beat the $2.10 estimate on $959.0M revenue (est. $876.6M).
−10.1%, on 5M shares, the year's heaviest volume · S&P 500 +0.7%
EPS of $3.29 beat the $2.59 estimate on $1.1B revenue (est. $1.0B).
+13.4%, the year's best day · S&P 500 +0.3%
Where it ended: a close of $165.92 on Nov 17, 2026. Up next: Q4 2026 earnings on Feb 10, 2027 (EPS est. $2.65, revenue est. $1.1B).
Nothing in the past 12 months.
All NBIX dividend historyReplay the year: the line draws itself and stops at each of the 6 moments with what happened and how the stock reacted.
Chart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for NBIX and SPY from Benzinga historical bars. Not investment advice.